NBNusrat Jihan Begum

Nusrat Jihan Begum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nusrat Jihan Begum has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Ambros J. Beer

    Department of Nuclear Medicine, Ulm University, Ulm, Germany

    2 shared publications
  • Gerhard Glatting

    Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany

    2 shared publications
  • Matthias Eiber

    Klinikum rechts der Isar, Department of Nuclear Medicine, Technical University of Munich School of Medicine, München, Germany

    2 shared publications
  • Peter Kletting

    Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany

    2 shared publications
  • Hans-Jürgen Wester

    Technical University of Munich, Pharmaceutical Radiochemistry, Munich, Germany

    1 shared publication

Latest Publications

  • An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands

    by Nusrat Jihan Begum, Gerhard Glatting, Matthias Eiber, Ambros J. Beer, Peter Kletting

    Aim The aim of this work was to systematically investigate the influence of the radionuclide half-life and affinity of prostate-specific membrane antigen (PSMA)-targeting ligands on the activity concentration for PET/CT imaging. Methods A whole-body physiologically-based pharmacokinetic (PBPK) model with individually estimated parameters of 13 patients with metastatic castration-resistant prostate cancer (mCRPC) was used to simulate the pharmacokinetics of PSMA-targeting radioligands. The simulations were performed with 68Ga (T1/2 = 1.13 h), 18F (T1/2 = 1.83 h), 64Cu (T1/2 = 12.7 h) and for different affinities (dissociation constants KD of 1–0.01 nM) and a commonly used ligand amount of 3 nmol. The activity concentrations were calculated at 1, 2, 3, 4, 8, 12, and 16 h after injection. Results The highest tumor uptake was achieved 1 h p. i. for 68Ga-PSMA. For 18F-PSMA, the highest tumor uptake was at 1 h p. i. and 2 h p.i for dissociation constants KD = 1 nM and KD = 0.1–0.01 nM, respectively. For 64Cu-PSMA, the highest tumor uptake was at 4 h p. i. for dissociation constant KD = 1 nM and at 4 h p. i. (9 patients) and 8 h p. i. (4 patients) for higher affinities. Compared to 68Ga-PSMA (1 h p. i.), the activity concentrations in the tumor for 18F-PSMA (2 h p. i.) increased maximum 1.3-fold with minor differences for all affinities. For 64Cu-PSMA (4 h p. i.), the improvements were in the range of 2.8 to 3.2-fold for all affinities. Conclusions The simulations indicate that the highest tumor-to-background ratio can be achieved after 4 hours in PET/CT using high-affinity 64Cu-PSMA. Ziel Ziel dieser Arbeit war es, den Einfluss der Radionuklid-Halbwertszeit und der Affinität von Prostata-spezifischen Membranantigen (PSMA)-adressierten Radioliganden auf die Aktivitätskonzentration für die PET/CT-Bildgebung systematisch zu untersuchen. Material und Methoden Ein physiologisch-basiertes pharmakokinetisches Ganzkörpermodell (PBPK) mit individuell geschätzten Parametern von 13 Patienten mit metastasiertem, kastrationsresistentem Prostatakarzinom (mCRPC) wurde verwendet, um die Pharmakokinetik von PSMA-adressierten Radioliganden zu simulieren. Die Simulationen wurden mit 68Ga (T1/2 = 1,13 h), 18F (T1/2 = 1,83 h), 64Cu (T1/2 = 12,7 h) und für verschiedene Affinitäten (Dissoziationskonstanten KD von 1–0,01 nM) und einer gebräuchlichen Ligandenmenge von 3 nmol durchgeführt. Die Aktivitätskonzentrationen wurden 1, 2, 3, 4, 8, 12 und 16 h nach Injektion berechnet. Ergebnisse Die höchste Tumoraufnahme wurde 1 h p. i. für 68Ga-PSMA erzielt. Für 18F-PSMA war die höchste Tumoraufnahme 1 h p. i. für die Dissoziationskonstanten KD = 1 nM bzw. 2 h p. i. für KD = 0,1–0,01 nM. Für 64Cu-PSMA war die höchste Tumoraufnahme 4 h p. i. für die Dissoziationskonstante KD = 1 nM und 4 h p. i. (9 Patienten) bzw. 8 h p. i. (4 Patienten) für höhere Affinitäten. Im Vergleich zu 68Ga -PSMA (1 h p. i.) erhöhten sich die Aktivitätskonzentrationen im Tumor für 18F-PSMA (2 h p. i.) maximal um das 1,3-fache mit geringen Unterschieden für alle Affinitäten. Bei 64Cu-PSMA (4 Std. p. i.) lagen die Verbesserungen bei allen Affinitäten im Bereich des 2,8- bis 3,2-fachen. Schlussfolgerung Die Simulationen zeigen, dass die höchste Tumor-to-Background-Ratio nach 4 Stunden im PET/CT mit hochaffinem 64Cu-PSMA erreicht werden kann. Received: 10 June 2020 Accepted: 02 September 2020 Article published online: 16 October 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model

    by Nusrat J. Begum, Gerhard Glatting, Hans-Jürgen Wester, Matthias Eiber, Ambros J. Beer, Peter Kletting

    The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) model for PSMA-specific ligands was implemented. Thirteen virtual patients with metastatic castration-resistant prostate cancer were analysed. Simulations were performed for different combinations of association rates kon (0.1–0.01 L/nmol/min), dissociation rates koff (0.1–0.0001 min−1), internalization rates λint (0.01–0.0001 min−1) and ligand amounts (1–1000 nmol). For imaging the activity was normalized to volume and injected activity (68Ga-PSMA at 1 h). For therapy the absorbed dose was calculated for 7.3 ± 0.3 GBq 177Lu-PSMA. The effect of the investigated parameters on therapy were larger compared to imaging. For imaging, the combination of properties leading to the highest tumour uptake was kon = 0.1 L/nmol/min, koff = 0.01 min−1 for typical ligand amounts (1–10 nmol). For therapy, the higher the internalization rate, the larger was the required ligand amount for optimal tumour-to-kidney ratios. The higher the affinity, the more important was the choice of the optimal ligand amount. PBPK modelling provides insight into the pharmacokinetics of PSMA-specific ligands. Further in silico and in vivo studies are required to verify the influence of the analysed parameters.